TABLE 2.
Events, cumulative incidence, and subdistribution hazard ratios (sHR) with 95% confidence interval (CI) for incident thrombotic events in patients with cancer initiating checkpoint inhibitor treatment: 6‐month follow‐up
| Venous thromboembolism | Arterial thrombosis | Any tromboembolism | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Events, n | Cumulative incidence a | sHR (95% CI) | Events, n | Cumulative incidence a | sHR (95% CI) | Events, n | Cumulative incidence a | sHR (95% CI) | |
| Overall | 99 | 2.6% | 52 | 1.3% | 148 | 3.8% | |||
| Single versus double checkpoint inhibitor treatment | |||||||||
| Single therapy | 89 | 2.5% | Ref. | 46 | 1.3% | Ref. | 132 | 3.7% | Ref. |
| Double therapy | 10 | 3.0% | 1.19 (0.62–2.30) | 6 | 1.8% | 1.38 (0.59–3.24) | 16 | 4.8% | 1.29 (0.77–2.17) |
| Khorana risk category | |||||||||
| 0: Low risk | 30 | 2.1% | Ref. | 13 | 0.9% | Ref. | 43 | 3.1% | Ref. |
| 1–2: Intermediate risk | 55 | 2.6% | 1.23 (0.79–1.92) | 31 | 1.5% | 1.60 (0.84–3.05) | 85 | 4.0% | 1.33 (0.92–1.92) |
| ≥3: High risk | 14 | 3.7% | 1.75 (0.93–3.30) | 8 | 2.1% | 2.31 (0.96–5.58) | 20 | 5.3% | 1.76 (1.03–2.99) |
| Guideline recommended threshold | |||||||||
| Score 0–1 | 52 | 1.9% | Ref. | 34 | 1.2% | Ref. | 86 | 3.1% | Ref. |
| Score ≥2 | 47 | 4.1% | 2.22 (1.50–3.30) | 18 | 1.6% | 1.28 (0.73–2.27) | 62 | 5.4% | 1.77 (1.28–2.46) |
a
Based on the cumulative incidence function considering death as competing risk.